Literature DB >> 8308469

Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: development of a specific radioimmunoassay for chromogranin A and its fragments.

M Stridsberg1, U Hellman, E Wilander, G Lundqvist, K Hellsing, K Oberg.   

Abstract

Chromogranin A is a well-known protein constituent in granules of neuroendocrine cells. It is also known that plasma levels of chromogranin A increase considerably in patients with neuroendocrine tumours and thus chromogranin A is used as a marker for these tumours. In the present study, we have shown that fragments of chromogranin A are excreted into the urine in some patients with carcinoid tumours. The chromogranin A molecule appeared in the urine N-terminally cleaved at amino acid positions 116 and 210, which are previously reported cleavage sites of the molecule. The fragments identified were mainly of about 35 kDa in size. The unprocessed chromogranin A molecule was not excreted in the urine. Five out of 40 patients excreting the fragments had slight tubular dysfunction in the kidneys. We also showed that these renally excreted split products of chromogranin A were immunogenic and could be used for production of antibodies against chromogranin A. These antibodies were used both for immunocytochemistry and for the development of a specific and sensitive radioimmunoassay for chromogranin A and its fragments. Measurements of plasma chromogranin A by radioimmunoassay appeared to be a better marker for tumour growth than were measurements of chromogranin A in the urine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8308469     DOI: 10.1677/joe.0.1390329

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  7 in total

1.  Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids.

Authors:  D Granberg; E Wilander; M Stridsberg; G Granerus; B Skogseid; K Oberg
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

2.  Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies.

Authors:  Rafael Molina; Elias Alvarez; Angeles Aniel-Quiroga; Maria Borque; Belen Candás; Antonio Leon; Rafael M Poyatos; Montserrat Gelabert
Journal:  Tumour Biol       Date:  2010-08-21

3.  Inhibition of angiogenesis induces chromaffin differentiation and apoptosis in neuroblastoma.

Authors:  E Wassberg; F Hedborg; E Sköldenberg; M Stridsberg; R Christofferson
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

4.  Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells.

Authors:  Eva Ludvigsen; Mats Stridsberg; John E Taylor; Michael D Culler; Kjell Oberg; Eva T Janson
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

5.  Chromogranin A Tubulopathy: Differing Histopathologic Patterns of Acute Tubular Injury in the Setting of Neuroendocrine Neoplasms.

Authors:  Miroslav Sekulic; Sushrut Waikar; Shveta S Motwani; Astrid Weins; Helmut G Rennke
Journal:  Kidney Int Rep       Date:  2019-05-08

6.  Low Efficacy of Chromogranin A Elimination by Therapeutic Plasma Exchange for Treatment of Chromogranin A Tubulopathy.

Authors:  Samy Hakroush; Laura Schridde; Manuel Wallbach; Ardian Mekolli; Peter Korsten; Björn Tampe
Journal:  Kidney Int Rep       Date:  2021-10-15

Review 7.  Biochemical diagnosis of neuroendocrine GEP tumor.

Authors:  K Oberg
Journal:  Yale J Biol Med       Date:  1997 Sep-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.